Alerta

用于重症肌无力治疗的耐受性免疫修饰纳米颗粒

Absstract of: AU2024245428A1

The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.

一种仿生锰基载药纳米颗粒及其制备方法和应用

Absstract of: CN121154854A

本发明提供了一种仿生锰基载药纳米颗粒及其制备方法和应用，涉及生物医药技术领域。本发明提供的仿生锰基载药纳米颗粒包括中空介孔二氧化锰纳米颗粒，由内而外依次包覆在所述中空介孔二氧化锰纳米颗粒外表面的牛血清白蛋白、具有抗肿瘤效果的单抗和PD‑1过表达肿瘤细胞膜，所述牛血清白蛋白与单抗之间通过与HOOC‑TK‑COOH发生酰胺缩合反应连接在一起；所述中空介孔二氧化锰纳米颗粒内负载有抗肿瘤药物。本发明提供的仿生锰基载药纳米颗粒可实现肿瘤部位的精准递送，具有良好的肿瘤靶向性，避免化疗药物全身循环带来的毒副作用；实现了免疫药物联合化疗药物的协同肿瘤治疗，可逆转肿瘤免疫抑制微环境，具有显著的肿瘤抑制效果。

一种超声辅助制备的白藜芦醇-蛋白纳米颗粒肠道靶向递送系统及其制备方法

Absstract of: CN121154523A

本发明涉及一种超声辅助制备的白藜芦醇‑蛋白纳米颗粒肠道靶向递送系统及其制备方法，属于功能性食品/医药递送系统技术领域。本发明白藜芦醇‑蛋白纳米颗粒肠道靶向递送系统的制备方法，包括以下步骤：S1：将白藜芦醇与超声处理水化蛋白充分结合，固液分离，得到负载白藜芦醇的蛋白纳米颗粒；S2：将负载白藜芦醇的蛋白纳米颗粒、乙酰化二淀粉磷酸酯和海藻酸钠充分混合，得到混合溶液；S3：将氯化钙与混合溶液混合，交联反应，得到所述白藜芦醇‑蛋白纳米颗粒肠道靶向递送系统。本发明保护白藜芦醇免受胃肠道环境破坏，提高其稳定性，实现肠道靶向及淀粉酶响应性释放，提高白藜芦醇生物利用度，在功能性食品和医药领域具有广阔的应用前景。

一种载核酸脂质纳米颗粒的冻干制剂的制备方法

Absstract of: CN121154559A

本发明公开了一种载核酸脂质纳米颗粒的冻干制剂的制备方法，涉及生物医药技术领域。本发明至少包括以下步骤：S1：配制含有载核酸脂质纳米颗粒和冻干保护剂的液体组合物；S2：降温进行预冻；S3：在真空条件下升温进行干燥，制备得到包含载核酸脂质纳米颗粒的冻干制剂。本发明制备方法能使载核酸脂质纳米颗粒的冻干制剂在2℃‑8℃条件下可以稳定储存至少24个月，极大提高了载核酸脂质纳米颗粒冻干制剂的稳定性，安全性更高，更具有市场竞争力。

一种红细胞辅助水滑石基纳米疫苗的免疫组合物及其制备方法、应用

Absstract of: CN121154800A

本发明涉及医药疫苗技术领域，公开了一种红细胞辅助水滑石基纳米疫苗的免疫组合物及其制备方法、应用，其中免疫组合物包括衰老红细胞和新鲜红细胞膜包被水滑石基纳米疫苗，水滑石基纳米疫苗包括水滑石基佐剂和外源性抗原，采用不同状态红细胞辅助的水滑石基纳米疫苗的免疫组合物的制备方法及其应用，在脾脏可诱导高效的DC细胞抗原交叉呈递，促进外源性抗原特异性免疫刺激，激活T细胞的免疫应答，并直接抑制实体肿瘤生长，肿瘤体积的抑制率达到60%。

膜脂包被纳米颗粒及其使用方法

Absstract of: US2020060979A1

Disclosed is a nanoparticle comprising an inner core comprising a virus; and an outer surface comprising a cellular membrane derived from a cell, and process of making thereof. The virus is an oncolytic virus and cellular membrane is derived from for example red blood cells.

α-酮戊二酸纳米微晶及其制备工艺

Absstract of: CN121154574A

本发明α‑酮戊二酸纳米微晶及其制备工艺，α‑酮戊二酸纳米微晶粒径范围为50‑300nm，动态光散射法测定，D90分布；晶型结构为单斜晶系，XRD特征峰位2θ＝12.3±0.2°，24.7±0.2°；比表面积≥35m2/g，BET氮吸附法测定。

M2M-SeMSN@C176纳米颗粒、制备方法及其应用

Absstract of: CN121154586A

本发明公开了M2M‑SeMSN@C176纳米颗粒、制备方法及其应用，该纳米颗粒包括STING抑制剂C176和载体两部分，载体基于M2巨噬细胞膜和桥接二硒的介孔二氧化硅纳米颗粒。具体地，M2M‑SeMSN@C176纳米颗粒是将STING抑制剂C176利用二硒桥接介孔二氧化硅纳米颗粒SeMSN、M2巨噬细胞膜负载而得。M2M‑SeMSN@C176纳米颗粒可用于急性肾损伤治疗药物的制备。

化合物在制备X射线敏化药物中的应用和药物组合物

Absstract of: CN121154806A

本发明涉及有机化合物在制备治疗或预防疾病的X射线敏化药物中的应用，疾病包括精神类疾病、肿瘤和癌症中的任意一种或多种，进一步优选为乳腺癌、结直肠癌、肺癌、肝癌、前列腺癌、急性髓性白血病、神经胶质瘤中的任意一种或多种，其中，所述的化合物的结构为：其中，R1＝C＝O、NH或NCH2CH2CH2N(CH3)2；R2＝H、Br、Cl、OH、OCH3、OCH2CH3、OCH2CH2CH3、OCH(CH3)2。本发明发现了该化合物具有良好的辐射诱导荧光和室温磷光发光性能。

一种阻断乳酸外排增强肿瘤光免疫治疗的组合物及其制备方法与应用

Absstract of: CN121154813A

本发明涉及一种阻断乳酸外排增强肿瘤光免疫治疗的组合物及其制备方法与应用，本发明通过靶向单羧酸转运蛋白4(MCT4)的乳酸代谢检查点阻断策略，共递送MCT4抑制剂昔洛舍平和光诊疗剂L8BO，以增强光免疫治疗。本发明的组合物L8@SY具有强大的分子内电荷转移效应、优化的单线态‑三线态能隙以及优异的光捕获能力，实现了I型和II型活性氧的同时生成，总活性氧产量在5分钟的光照时间内高达503倍，同时还具有高达46.2％的光热转换效率。在乳酸外排阻断诱导细胞内酸化的触发下，基于本发明组合物的纳米颗粒展现出卓越的抑瘤效果，近乎完全抑制了原发肿瘤(抑制率99.6％)，显著抑制了远端肿瘤(抑制率68.6％)，同时减少了肺转移。

一种基于自体抗原及合成抗原的抗肿瘤疫苗制备方法与应用

Absstract of: CN121154799A

本发明涉及疫苗技术领域，公开了一种基于自体抗原及合成抗原的抗肿瘤疫苗制备方法与应用。所述抗肿瘤疫苗包括肿瘤自体抗原与合成抗原；其中，所述肿瘤自体抗原提取自肿瘤细胞膜、肿瘤细胞裂解物、肿瘤细胞分泌物、外泌体抗原或肿瘤微环境释放的抗原；所述合成抗原选自肿瘤相关抗原、肿瘤特异性抗原、个性化新抗原、病原体抗原、生物毒素、生物分子抗原、以及上述抗原中肽型抗原的编码核酸中的至少一种；所述编码核酸为DNA或mRNA。本发明由肿瘤自体抗原与合成抗原组成的疫苗分子易于制备，具有强力的抗肿瘤免疫效果和良好的生物安全性，解决了传统肿瘤自体抗原无特异性精准靶点以及合成抗原免疫原单一的问题，具备广阔的应用前景。

一种负载雷公藤甲素的纳米共递送给药载体及其在制备治疗间质性膀胱炎的药物中的应用

Absstract of: CN121154579A

本发明属于外泌体应用技术领域，公开了一种负载雷公藤甲素的纳米共递送给药载体及其在制备治疗间质性膀胱炎的药物中的应用。所述负载雷公藤甲素的纳米共递送给药载体用于间质性膀胱炎模型动物，观察到有以下变化：1、模型动物对刺激敏感性降低；2、模型动物排尿次数减少，且单词排尿量增加；3、模型动物的尿液中血红细胞数量减少；4、膀胱组织充血得到了缓解，体积变小；5、炎症因子IL‑6、MCP‑1、ICAM‑1和BAX的表达显著降低。由此可以确定将负载雷公藤甲素的纳米共递送给药载体用于治疗间质性膀胱炎。本研究拓开了雷公藤甲素的应用范围，将其与外泌体结合用于治疗间质性膀胱炎，从而为间质性膀胱炎的治疗提供了新的思路。

一种基于谷胱甘肽驱动的纳米硒材料及其制法与应用

Absstract of: CN121154679A

本发明涉及纳米硒材料技术领域，具体涉及一种基于谷胱甘肽驱动的纳米硒材料及其制法与应用，该纳米硒材料为采用谷胱甘肽和亚硒酸钠通过一锅水热法合成制得，其制备方法简单易行，制得的GSH‑Se纳米颗粒包括纳米硒核心和谷胱甘肽修饰外壳，其溶液具有优异的胶体稳定性及广谱的自由基清除特性。同时，本发明提供的GSH‑Se纳米颗粒具有改善帕金森病、促进线粒体稳态、减轻神经炎症、改善多巴胺能神经元功能及运动行为障碍等作用，具有极大的临床应用价值。

LIPID NANOPARTICLE FORMULATION FOR DELIVERY OF NUCLEIC ACIDS TO CELLS

Absstract of: WO2025260068A1

Provided are lipid nanoparticles (LNPs) and compositions thereof for delivery of nucleic acid molecules, e.g., ribonucleic acid (RNA), into cells, such as primary cells e.g., T cells, or induced cells, e.g., iPSCs and cells differentiated from iPSCs. Also provided are methods for formulating LNPs, and for delivering nucleic acid molecules into cells, primary cells or induced cells using LNP compositions, including in connection with modulating gene expression using DNA targeting systems.

MULTIPLEXED ASSEMBLIES OF PROTEINS FOR TARGETED DRUG AND GENE DELIVERY

Absstract of: WO2025259853A1

Disclosed is bottlebrush polymer containing (i) a saturated polyolefin backbone and (ii) a plurality of hydrophilic polymer side chains, wherein a plurality of different proteins is covalently conjugated to the plurality of side chains. By incorporating a plurality of different proteins, this platform can be utilized to modulate the biodistribution profile of delivery vehicles, and thereby target major organs. The plurality of side chains contains polyethylene glycol (PEG) having a weight-average molecular weight or number-average molecular weight between 150 Da and 1 kDa. The data show that a particle containing a bottlebrush polymer described herein demonstrated significantly improved circulation half-life in the blood compared to a corresponding particle that did not include a plurality of proteins. This property can be harnessed for passive accumulation of particles (e.g., nanoparticles, microparticles, etc.) in diseased cells, tissues, or organs. In preferred forms, the proteins are serum proteins and/or genetically engineered proteins.

TUMOUR SENSITISATION

Absstract of: WO2025257545A1

The present invention relates to methods of sensitising a subject having a cancer or a pre-cancer to treatment with an immune checkpoint inhibitor, as well as compositions for use in sensitising a subject to such treatment.

METHODS AND COMPOSITIONS FOR TRANSFECTING CELLS

Absstract of: WO2025257289A2

Provided herein are methods and compositions for transfecting cells or an organism comprising the cells for use as therapeutic, medicinal products, or consumption products or generating thereof. The compositions may comprise a saccharide, a nucleic acid molecule, and/or a lipid molecule. The compositions and methods may promote or facilitate uptake of a nucleic acid by the cells.

NOVEL N-SUBSTITUTED POLYGLYCINE LIPIDS

Absstract of: WO2025257438A1

The present invention relates to a compound of formula (I), (II), (III), (IV), (V) or (VI) (I), (II), (III), (IV), (V), (VI), wherein cor128wo R1 and R2 are independently selected from the groups consisting of -C10-C30 alkyl, -C10- C30 alkenyl, -C(=O)-C9-C29 alkyl or -C(=O)-C9-C29 alkenyl, R3 and R7 are each -H, or -CH3, R4 is selected from the groups consisting of -C1-C4 alkyl, -C1-C4 alkyl-NR9 2, -C1-C4 alkyl- OR9, wherein R9 is independently selected from -H, and the groups consisting of -C1-C3 alkyl or -C(=O)-C1-C3 alkyl, R5 and R6 are independently selected from -H, and the groups consisting of -C1-C3 alkyl or -C(=O)-C1-C3 alkyl, Y is selected from the group consisting of -C1-C6 alkyl, R8 is selected from the group consisting of -C6-C12 alkyl, X is selected from -O-, -S-, -NH-, and -NMe-, and (VII), p is 1 or 2, and q is 1 or 2, and wherein the sum of q and p is 2 or 3, r is 0, 1 or 2, and s is 0, 1, or 2, and wherein the sum of r and s is 1 or 2, n is an integer in the range of 0 to 80, and m and l are each an integer in the range of 1 to 80.

LIPID COMPOSITION

Absstract of: WO2025257084A1

The present invention relates to a lipid composition for lipid nanoparticles (LNP), which comprises: (a) one or more cationic and/or cationically ionizable lipids; (b) a sterol; (c) one or more helper lipids; and (d) a lipid obtainable by a method comprising (i) subjecting a mixture comprising one or more monomers of the following formula (I), (I) wherein R1 represents an ethyl group, R3 and R4, which may be the same or different, independently represent a hydrogen atom, or a C1-2 alkyl group, to cationic ring opening polymerization in the presence of a polymerization initiator for providing a linear polymer; and (ii) introducing a terminal group R2 of the following formula (II): (II) wherein k is an integer of 1 so that a spacer exists between the polyoxazoline chain and Z, whereby the structure of the spacer is determined by the repeating units y and z; y is 0 or an integer of 1 to 3, and z is 0 or an integer of 1 to 3; a which may be the same or different when more than one is present, represents an integer of 1 to 6; b represents 0 or an integer of 1 to 6; X1 which may be the same or different when more than one is present, independently represents an oxygen atom, a group -O-CO-, -N-CO-, or -NR' wherein R' is a hydrogen atom or an alkyl group; X2 which may be the same or different when more than one is present, represents a single bond or a group -CO-; X3 which may be the same or different when more than one is present, independently represents a single bond, an oxygen at

LIPID NANOPARTICLES USING CATIONIC CHOLESTEROL FOR LOCAL DELIVERY FOR NUCLEIC ACID DELIVERY

Absstract of: US2025381140A1

The present invention is directed to lipid nanoparticles using cationic cholesterol for topical delivery for nucleic acid delivery, and when administered locally, side effects caused by systemic drug delivery can be minimized and protein expression can be confined to the site of administration. In addition, the duration of protein expression at the site of administration can be increased, and thus the lipid nanoparticles can be useful in the technical field related to nucleic acid therapeutics.

CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS

Absstract of: US2025381149A1

The present invention relates to a method and compositions for optimized cytosolic delivery of active agents, in particular nucleic acids, using a specific class of cationic amphiphilic compounds. The method and compositions of the invention enhance intracellular release of the agents and can be used for the treatment of various disorders.

Long-Lasting Anaesthetic Formulation

Absstract of: US2025381173A1

The present invention is within the technical field of pain-relief and relates to a pharmaceutical composition comprising at least one anesthetic agent selected from the group consisting of ropivacaine, bupivacaine, etidocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, articaine, dibucaine, levobupivacaine, prilocaine, benzocaine, chloroprocaine, cocaine, procaine, proparacaine, tetracaine and any pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof; at least one alkanolamine selected from the group consisting of triethanolamine, tripropanolamine and trimethanolamine; water; and optionally a pharmaceutically acceptable diluent, carrier and/or excipient. The present disclosure furthermore relates to the use of the composition for providing pain-relief, a method of treatment, a method of producing said pharmaceutical composition as well as a carbon quantum dot formed from components of the pharmaceutical composition.

METHODS FOR LIPID NANOPARTICLE DELIVERY OF CRISPR/CAS SYSTEM

Absstract of: US2025381213A1

This disclosure relates to methods treating cancer comprising administering to a subject in need thereof a lipid nanoparticle comprising a therapeutically effective amount of a CRISPR/Cas system comprising one or more nucleic acid sequences encoding one or more guide RNAs (gRNAs) that are complementary to one or more target sequences in a cancer gene of a cancer cell and a nucleic acid sequence encoding a CRISPR-associated endonuclease.

TABLETIZATION OF PEPTIDE SELF-ASSEMBLIES AND METHODS OF MAKING AND USING THE SAME

Absstract of: US2025381144A1

The present disclosure provides, in part, peptide self-assemblies that are made into tablet form and methods of making and using the same. In some embodiments, the disclosure provides methods and formulations for a tabletized form of a vaccine, particularly a vaccine comprising self-assembling peptide-polymer nanofibers, an excipient and an adjuvant. Methods of making and using the tablet formulation are also provided.

LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS

Nº publicación: US2025382640A1 18/12/2025

Applicant:

JUNO THERAPEUTICS INC [US]
Juno Therapeutics, Inc

Absstract of: US2025382640A1

The present disclosure relates to compositions comprising lipid nanoparticles for delivering nucleic acid molecules into cells. Also included are methods for producing and using such compositions.